What is ABOLIS?
ABOLIS is at the forefront of delivering high-impact innovations designed to support industries in their transition towards a more sustainable future, achieved through collaboration with nature. The company specializes in providing tailor-made industrial solutions that leverage micro-organisms. These advanced solutions cater to a diverse array of sectors, including food and healthcare, as well as cosmetics and chemistry, demonstrating ABOLIS's broad applicability and commitment to ecological advancement.
How much funding has ABOLIS raised?
ABOLIS has raised a total of $38.7M across 1 funding round:
Other Financing Round
$38.7M
Other Financing Round (2024): $38.7M with participation from L'Oreal Bold Ventures, Evonik Venture Capital, and DeepTech & Climate Fonds
Key Investors in ABOLIS
L'Oreal Bold Ventures
L'Oreal Bold Ventures is an investment arm focused on new and disruptive business models, aligning with ABOLIS's innovative approach.
Evonik Venture Capital
Evonik Venture Capital is an investor in ABOLIS, contributing to the company's strategic financing.
DeepTech & Climate Fonds
DeepTech & Climate Fonds is a venture capital fund focused on long-term investments in early growth ventures across Germany and Europe, particularly in DeepTech and ClimateTech.
What's next for ABOLIS?
With this substantial strategic investment, ABOLIS is poised for accelerated growth and enhanced market penetration. The capital will likely fuel further research and development into novel bio-based solutions, expanding their industrial applications and reinforcing their position as a leader in nature-inspired innovation. This funding round signals strong confidence from investors in ABOLIS's mission to foster a better future through sustainable industrial practices.
See full ABOLIS company page
